Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

ID#: NCT00736749

Age: Birth - 66+

Gender: All

Healthy Subjects: No

Recruitment Status: Recruiting

Start Date: May 01, 2008

Summary: This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Eligibility:

Inclusion Criteria:

- The patient must be enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy;or the patient must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1

- Hodgkin lymphoma

- CCG 5942

- POG 9425

- POG 9426

- AHOD0031

- AHOD1331

- S1826 (COG patients only)

- Brain tumor

- A9961

- Acute lymphoblastic leukemia

- POG 9404

- Osteosarcoma

- POG 9754

- Stem cell transplantation

- ASCT0631D

- Rhabdomyosarcoma

- IRS-III

- IRS-IV

- Late Effects Protocols with Patients Eligible for Enrollment on ALTE05N1

- ALTE15N1

- ALTE16C1

- Enrollment on ALTE05N1 must occur within 24 calendar months of the date the patient was enrolled on a frontline COG therapeutic trial; or patients previously enrolled on a COG (or Legacy Group) trial targeted for long term follow-up by ALTE05N1 may enroll on ALTE05N1 at any time

- The patient must reside in the U.S. on the date of enrollment to ALTE05N1

- All patients and/or their parents or legal guardians must sign a written informed consent

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met